IN2015DN02875A - - Google Patents

Info

Publication number
IN2015DN02875A
IN2015DN02875A IN2875DEN2015A IN2015DN02875A IN 2015DN02875 A IN2015DN02875 A IN 2015DN02875A IN 2875DEN2015 A IN2875DEN2015 A IN 2875DEN2015A IN 2015DN02875 A IN2015DN02875 A IN 2015DN02875A
Authority
IN
India
Prior art keywords
enzalutamide
disclosure provides
hyperproliferative disorders
provides formulations
treating hyperproliferative
Prior art date
Application number
Other languages
English (en)
Inventor
Douglas Alan; Lorenz
Sanjay; Konagurthu
Randy J ; Wald
Jason A ; Everett
Sheila; Matz
Yuuki; Takaishi
Toshiro; Sakai
Ryousuke; Irie
Shinsuke; Oba
Hiroyasu; Toyota
Koji; Nishimura
Atsushi; Kanbayashi
Original Assignee
Medivation Prostate Therapeutics Inc
Bend Res
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN02875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Inc, Bend Res, Astellas Pharma Inc filed Critical Medivation Prostate Therapeutics Inc
Publication of IN2015DN02875A publication Critical patent/IN2015DN02875A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
IN2875DEN2015 2012-09-11 2013-09-11 IN2015DN02875A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699351P 2012-09-11 2012-09-11
PCT/US2013/059223 WO2014043208A1 (en) 2012-09-11 2013-09-11 Formulations of enzalutamide

Publications (1)

Publication Number Publication Date
IN2015DN02875A true IN2015DN02875A (zh) 2015-09-11

Family

ID=49231627

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2875DEN2015 IN2015DN02875A (zh) 2012-09-11 2013-09-11

Country Status (28)

Country Link
US (9) US20140179749A1 (zh)
EP (5) EP4169908A1 (zh)
JP (5) JP6404217B2 (zh)
KR (1) KR102225416B1 (zh)
CN (2) CN105358535B (zh)
AU (2) AU2013315619B2 (zh)
BR (1) BR112015005432B1 (zh)
CA (1) CA2884795C (zh)
CY (1) CY1124729T1 (zh)
DK (1) DK3725778T3 (zh)
EA (2) EA201991484A1 (zh)
ES (1) ES2892029T3 (zh)
HK (1) HK1212701A1 (zh)
HR (1) HRP20211423T1 (zh)
HU (1) HUE057701T2 (zh)
IL (1) IL237604B (zh)
IN (1) IN2015DN02875A (zh)
LT (1) LT3725778T (zh)
MX (3) MX363974B (zh)
PH (1) PH12015500525A1 (zh)
PL (1) PL3725778T3 (zh)
PT (1) PT3725778T (zh)
RS (1) RS62676B1 (zh)
SI (1) SI3725778T1 (zh)
TW (1) TWI673051B (zh)
UA (1) UA117353C2 (zh)
WO (1) WO2014043208A1 (zh)
ZA (1) ZA201501847B (zh)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169908A1 (en) 2012-09-11 2023-04-26 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
KR20210013342A (ko) 2012-09-26 2021-02-03 아라곤 파마슈티컬스, 인코포레이티드 비전이성 거세 저항성 전립선암 치료용 항안드로겐
WO2014172431A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CN106102716A (zh) * 2014-02-05 2016-11-09 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
AU2015358493B2 (en) * 2014-12-05 2021-05-06 Aragon Pharmaceuticals, Inc. Anticancer compositions
CA2969675C (en) 2014-12-05 2023-06-06 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
CN104546714A (zh) * 2015-02-11 2015-04-29 江苏慧博生物科技有限公司 一种恩杂鲁胺胶束制剂及其制备方法
CA2976360A1 (en) * 2015-02-11 2016-08-18 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
US20180235935A1 (en) 2015-08-12 2018-08-23 Medivation Prostate Therapeutics Llc Treatment of Cancer with Enzalutamide and a CYP3A4 Inhibitor
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
US11478453B2 (en) 2016-07-21 2022-10-25 Hadasit Medical Research Services And Development Ltd. Treatment for glioblastoma
EP3500310A1 (en) 2016-08-20 2019-06-26 FTF Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
AU2018252153A1 (en) * 2017-04-13 2019-11-07 Jean Paul Remon Xanthohumol-based compositions
AU2018256998B2 (en) 2017-04-28 2023-11-09 Astellas Pharma Inc. Pharmaceutical composition for oral administration comprising
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
WO2019030691A1 (en) * 2017-08-08 2019-02-14 Dr. Reddy’S Laboratories Limited EXTRUDED COMPOSITIONS OF ENZALUTAMIDE
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
US20200397756A1 (en) * 2018-02-09 2020-12-24 Kashiv Biosciences, Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
CN112004529B (zh) 2018-04-06 2023-08-08 比利时胶囊公司 包含聚[(甲基丙烯酸甲酯)-共-(甲基丙烯酸)]的低纵横比颗粒的喷雾干燥方法
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
EA202191372A1 (ru) * 2018-12-14 2021-09-16 Фуджифилм Корпорэйшн Таблетка и способ получения таблетки
CN109432016B (zh) * 2018-12-26 2021-03-02 广州中医药大学(广州中医药研究院) 一种恩杂鲁胺的三元固体制剂及其制备方法
WO2020144646A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Apalutamide dispersed in applesauce for treating prostate cancer
EP3918607A1 (en) 2019-01-30 2021-12-08 Janssen Pharmaceutica NV Methods of treating prostate cancer based on molecular subtypes
US20220133638A1 (en) 2019-05-16 2022-05-05 Leon-Nanodrugs Gmbh Method for producing nanoparticles
JP2022533463A (ja) 2019-05-23 2022-07-22 ヘルム・アクチエンゲゼルシャフト エンザルタミドを含むナノ粒子
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3990435A1 (en) 2019-06-27 2022-05-04 Synthon B.V. Process for preparation of enzalutamide
MX2022003146A (es) * 2019-09-18 2022-04-06 Bristol Myers Squibb Co Formas de dosificacion de liberacion prolongada para los inhibidores de tirosina cinasa 2 (tyk2).
MX2022003347A (es) * 2019-09-23 2022-04-11 Bionomics Ltd Formulaciones terapeuticas y usos de las mismas.
CA3152909A1 (en) 2019-10-03 2021-04-08 Synthon Bv Pharmaceutical composition comprising enzalutamide
EP4054572A1 (en) 2019-11-04 2022-09-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN114053243A (zh) * 2020-08-05 2022-02-18 齐鲁制药有限公司 一种恩扎卢胺软胶囊及其制备方法
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
CN115721612A (zh) * 2021-08-26 2023-03-03 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法
WO2023138366A1 (zh) * 2022-01-19 2023-07-27 四川科伦药物研究院有限公司 固体分散体及其制备方法和包含其的药物组合物
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
WO2023244617A1 (en) * 2022-06-13 2023-12-21 Virginia Polytechnic Institute And State University Amphiphilic cellulose derivatives, methods of making, and uses thereof
WO2023244684A1 (en) * 2022-06-17 2023-12-21 Tranquis Therapeutics, Inc. Formulations of 2-arylbenzimidazole compounds
CN115887395A (zh) * 2022-11-18 2023-04-04 上海药坦药物研究开发有限公司 恩杂鲁胺固体分散体制剂及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
IN191496B (zh) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
NZ527532A (en) 2001-02-27 2004-12-24 Astrazeneca Ab Pharmaceutical formulation comprising bicalutamide
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
SE0103839D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
MXPA04007435A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion.
WO2003089499A1 (en) 2002-04-18 2003-10-30 Avecia Limited Prepation of a conjugated molecule and materials for use therein
JP4249950B2 (ja) 2002-06-28 2009-04-08 富士フイルム株式会社 紙管切断装置及び紙管切断方法
AU2003209667A1 (en) 2003-02-21 2004-09-09 Hetero Drugs Limited Bicalutamide polymorphs
WO2005095950A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
PL2444085T3 (pl) 2005-05-13 2015-07-31 Univ California Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP1909762A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Amorphous efavirenz and the production thereof
ES2863798T3 (es) 2006-03-27 2021-10-11 Univ California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US20100151035A1 (en) 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
KR101569227B1 (ko) 2008-03-11 2015-11-13 아스카 세이야쿠 가부시키가이샤 고체 분산체와 그 의약 조성물, 그리고 그들의 제조 방법
MX2011008303A (es) 2009-04-03 2011-11-29 Plexxikon Inc Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas.
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
SI2538785T1 (en) * 2010-02-24 2018-05-31 Medivation Prostate Therapeutics Llc Methods for the synthesis of diarylthiohidantoin and diarylhydantoin compounds
SG183985A1 (en) * 2010-03-10 2012-10-30 Abbott Lab Solid compositions
PT2858985T (pt) 2012-06-07 2018-07-10 Sloan Kettering Inst Cancer Res Formas cristalinas de um modulador do recetor de androgénio
TWI595715B (zh) * 2012-08-10 2017-08-11 奇沙公司 用於極高頻通訊之介電耦接系統
BR112015005404A2 (pt) 2012-09-11 2017-08-22 Dr Reddys Laboratories Ltd Formas polimórficas de enzalutamida e sua preparação
US9713594B2 (en) 2012-09-11 2017-07-25 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
EP4169908A1 (en) 2012-09-11 2023-04-26 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
AU2018256998B2 (en) 2017-04-28 2023-11-09 Astellas Pharma Inc. Pharmaceutical composition for oral administration comprising
US20190208236A1 (en) 2018-01-02 2019-07-04 Source Digital, Inc. Coordinates as ancillary data
CA3152909A1 (en) 2019-10-03 2021-04-08 Synthon Bv Pharmaceutical composition comprising enzalutamide

Also Published As

Publication number Publication date
KR20150082203A (ko) 2015-07-15
EP3725778A1 (en) 2020-10-21
RS62676B1 (sr) 2021-12-31
US20230210778A1 (en) 2023-07-06
CA2884795A1 (en) 2014-03-20
MX2019003984A (es) 2019-08-12
PL3725778T3 (pl) 2021-12-20
EA033374B1 (ru) 2019-10-31
CA2884795C (en) 2023-10-17
JP2015527411A (ja) 2015-09-17
MX2015003140A (es) 2015-12-16
EP4324527A3 (en) 2024-04-24
CY1124729T1 (el) 2022-07-22
ZA201501847B (en) 2016-01-27
AU2013315619A1 (en) 2015-04-30
EP4169908A1 (en) 2023-04-26
US20170027910A1 (en) 2017-02-02
US20140100256A1 (en) 2014-04-10
KR102225416B1 (ko) 2021-03-09
EA033374B9 (ru) 2019-12-18
ES2892029T3 (es) 2022-02-01
DK3725778T3 (da) 2021-09-20
EA201500314A1 (ru) 2015-12-30
EA201991484A1 (ru) 2019-11-29
IL237604B (en) 2021-07-29
PH12015500525A1 (en) 2015-05-04
US20230122911A1 (en) 2023-04-20
CN109897004A (zh) 2019-06-18
SI3725778T1 (sl) 2022-02-28
AU2013315619B2 (en) 2018-02-08
JP6932746B2 (ja) 2021-09-08
EP3725778B1 (en) 2021-08-18
BR112015005432A2 (zh) 2017-09-05
US20140179749A1 (en) 2014-06-26
JP2018087206A (ja) 2018-06-07
EP4324527A2 (en) 2024-02-21
EP3971167A1 (en) 2022-03-23
US20170224624A1 (en) 2017-08-10
CN105358535B (zh) 2019-01-04
US20200060976A1 (en) 2020-02-27
HK1212701A1 (zh) 2016-06-17
PT3725778T (pt) 2021-09-22
JP2016204392A (ja) 2016-12-08
JP2021178871A (ja) 2021-11-18
WO2014043208A1 (en) 2014-03-20
US20190209476A1 (en) 2019-07-11
HUE057701T2 (hu) 2022-05-28
MX363974B (es) 2019-04-10
JP2019194262A (ja) 2019-11-07
LT3725778T (lt) 2021-12-27
US11839689B2 (en) 2023-12-12
MX2021000007A (es) 2021-03-09
CN105358535A (zh) 2016-02-24
AU2018200316A1 (en) 2018-02-08
UA117353C2 (uk) 2018-07-25
IL237604A0 (en) 2015-04-30
US20140378517A1 (en) 2014-12-25
EP2895463A1 (en) 2015-07-22
TWI673051B (zh) 2019-10-01
JP6404217B2 (ja) 2018-10-10
BR112015005432B1 (pt) 2023-04-18
TW201427659A (zh) 2014-07-16
HRP20211423T1 (hr) 2022-01-21

Similar Documents

Publication Publication Date Title
PH12015500525A1 (en) Formulations of enzalutamide
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
HK1217289A1 (zh) 使用細菌治療癌症的組合物和方法
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
IN2015DN00127A (zh)
MY168032A (en) Warm-Cool Beauty Treatment Device
IN2014DN11201A (zh)
IL238177A0 (en) Methods and preparations for the treatment of cancer
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
EP2897689A4 (en) COMPOSITIONS AND METHODS OF TREATING ALOPEZIA
IL239374A0 (en) Preparations and methods for treating brain tumors
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
ZA201408055B (en) Compositions and methods for the treatment of local pain
GEP201706764B (en) Quinazolin-thf-amines as pde1 inhibitors
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP2825184A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
MY168958A (en) Intermediates and processes for preparing compounds
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
AU2012902296A0 (en) Compositions for Therapy and Methods of Treatment